Répertoire du corps professoral

Prédiction précoce thrombo-embolie - Molecular signature
Organisme(s) subventionnaire(s): Fondation du CHU de Québec
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 décembre 2025 au 31 mars 2030

Prédiction précoce thrombo-embolie - Biomarqueurs
Organisme(s) subventionnaire(s): Fondation du CHU de Québec
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 décembre 2025 au 31 mars 2030

Early prediction and clinical impact of venous thrombo-embolism in children with cancer
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 octobre 2025 au 30 septembre 2030

Incidence et impact des saignements menstruels abondants chez les adolescents traités avec anticoagulation
Organisme(s) subventionnaire(s): Fondation du CHU de Québec
Type de financement: Subvention
Établissement tête: Université Laval
Du 20 mars 2025 au 31 mars 2027

Tirer profit des données de soins en contexte réel pour une introduction responsable, efficiente et équitable des innovations thérapeutiques en oncologie : la plateforme MEDOnco-VieRéelle
Programme: Mise sur pied de la plateforme PROVEM
Organisme(s) subventionnaire(s): Fonds de recherche du Québec - Santé
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 septembre 2024 au 31 août 2027

Fonds de démarrage pour chercheurs en debut de carrière –Bourse de recrutement étudiant
Programme: Soutien facultaire aux jeunes chercheurs de la Faculté de médecine
Organisme(s) subventionnaire(s): Université Laval - Fonds internes
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 juillet 2023 au 30 juin 2027

Impact clinique et prédiction précoce de la thrombo-embolie veineuse chez l'enfant atteint de cancer
Programme: Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors
Organisme(s) subventionnaire(s): Fonds de recherche du Québec - Santé
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 juillet 2023 au 30 juin 2027

Impact clinique et prediction precoce de la thrombo-embolie veineuse chez l'enfant atteint de cancer- Subvention établissement de jeunes chercheurs
Programme: Établissement de jeunes chercheurs - Juniors 1
Organisme(s) subventionnaire(s): Fonds de recherche du Québec - Santé
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2023 au 31 mars 2027

Financements des 2 dernières années

Early prediction and clinical impact of venous thrombo-embolism in children with cancer
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 mars 2025 au 28 février 2026

Biomarkers for prediction of venous thrombo-embolism in children with cancer
Programme: Subvention en recherche clinique (PRCE)
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 23 janvier 2024 au 31 décembre 2024

Étude pilote sur l'histoire naturelle des thromboses asymptomatiques sur cathéters veineux centraux chez les enfants atteints de cancer
Programme: Soutien aux chercheurs
Organisme(s) subventionnaire(s): Fondation du CHU de Québec, CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 16 septembre 2022 au 31 mars 2026

Fonds de démarrage - Nouveau chercheur
Programme: Fonds de démarrage
Organisme(s) subventionnaire(s): Fondation du CHU de Québec, CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 janvier 2020 au 31 mars 2025

Aiman Youssoufou, Maîtrise en épidémiologie - avec mémoire

Marie-Pier Desjardins, Doctorat en sciences cliniques et biomédicales

Gérald Guillebaud, Doctorat en sciences cliniques et biomédicales

Publications des 5 dernières années

Asparaginase activity levels and toxicity in children and adolescents with acute lymphoblastic leukemia Leukemia & Lymphoma, 2026/07/03. Marie-Claude Pelland-Marcotte, Chantal Éthier, Alexis Manirakiza, Heloise Perrault, Elsa Trombino, Caroline Laverdière, Tiago Nava, Yves Théorêt, Jean-Marie Leclerc, James A. Whitlock, Émilie Martineau, Marie-Pier Desjardins, Mahukpe Narcisse U. Singbo, Thai Hoa Tran. DOI 10.1080/10428194.2026.2656726

Incidence of neonatal venous thromboembolism: a systematic review and meta-analysis of the literature Research and Practice in Thrombosis and Haemostasis, 2026/05. Marie-Claude Pelland-Marcotte, Norma Maria Herrera Perez, Elisabeth Boileau, Eve Bouhêlier, Heleen van Ommen, Rukhmi Bhat. DOI 10.1016/j.rpth.2026.106630

Contemporary management of pediatric venous thrombosis: how does it differ from adult care? Journal of Thrombosis and Haemostasis, 2026/05. Alexandra Zabeida, Hui Yin Lim, Amy L. Kiskaddon, Hollie Gilmore, Paul Monagle, Marie-Claude Pelland-Marcotte. DOI 10.1016/j.jtha.2026.04.039

Rivaroxaban for extended anticoagulation of pediatric venous thromboembolism TRANSLATIONAL PEDIATRICS, 2026. DOI 10.21037/TP-2026-1-0130

Incidence and Risk Factors of Serious Osteonecrosis in Pediatric Acute Lymphoblastic Leukemia: A CYP-C Population-Based Study PEDIATRIC BLOOD & CANCER, 2026. DOI 10.1002/1545-5017.70271

Incidence and Outcome of Infants With Cancer in Canada: A Report From Cancer in Young People in Canada Database PEDIATRIC BLOOD & CANCER, 2026. DOI 10.1002/1545-5017.70050

Factors Associated With Thromboembolism in Neonates A Systematic Review and Meta-Analysis JAMA NETWORK OPEN, 2026. DOI 10.1001/JAMANETWORKOPEN.2026.10908

Clinical outcomes following catheter-related venous thrombo-embolism among children with acute lymphoblastic leukemia THROMBOSIS RESEARCH, 2026. DOI 10.1016/J.THROMRES.2026.109691

Changes in childhood cancer incidence rates and trends in Canada (2001-2023): Results from the Cancer in Young People in Canada surveillance program CANCER EPIDEMIOLOGY, 2026. DOI 10.1016/J.CANEP.2026.103106

Cancer outcome among adolescents in Canada. JOURNAL OF CLINICAL ONCOLOGY, 2026. DOI 10.1200/JCO.2026.44.16_SUPPL.10024

An international survey on current practices of management of neonatal catheter-associated venous thromboembolism: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2026. DOI 10.1016/J.JTHA.2026.02.028

ASH/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism BLOOD ADVANCES, 2026. DOI 10.1182/BLOODADVANCES.2025019415

Impact of Obesity and Overweight on Heparin Dosing and Clinical Outcomes in Pediatric Patients with Venous Thromboembolism Thrombosis and Haemostasis, 2026/01. Alexandra Larouche, Valérie Dollo, Gabriel Mercier, Narcisse Singbo, Chantal Éthier, Marie-Christine Boulanger, Marie-Claude Pelland-Marcotte. DOI 10.1055/a-2544-6183

Inhibitor Development in Severe Congenital Factor V Deficiency Journal of Pediatric Hematology/Oncology, 2025/10. Clara Guilbault, Arnaud Bonnefoy, Georges-Étienne Rivard, Marie-Claude Pelland-Marcotte. DOI 10.1097/MPH.0000000000003099

Long-term impact of central venous catheters in pediatric cancer survivors Research and Practice in Thrombosis and Haemostasis, 2025/07. Tasha Cusson, Jessica Giguère, Émilie Martineau, Chantal Éthier, André Lamarre, Marie-Claude Pelland-Marcotte. DOI 10.1016/j.rpth.2025.102986

Title: Role of primary VTE prophylaxis in pediatric leukemia, lymphoma, and solid tumors: A systematic review and meta-analysis. BLOOD, 2025. DOI 10.1182/BLOOD-2025-3139

Thromboembolism and event-free survival in children with extracranial solid tumors: A report from CYP-c BLOOD, 2025. DOI 10.1182/BLOOD-2025-706

Safety and effectiveness of standard versus extended duration of anticoagulation in children with acute lymphoblastic leukemia and venous thrombo-embolism BLOOD, 2025. DOI 10.1182/BLOOD-2025-3123

Role in of primary VTE prophylaxis in pediatric patients in hospitalized and critically ill settings: A systematic review and meta BLOOD, 2025. DOI 10.1182/BLOOD-2025-3137

Risk factors for thrombo-embolism in neonates: A systematic review of the literature and call to action BLOOD, 2025. DOI 10.1182/BLOOD-2025-4900

Prognostic Impact of Age in Pediatric Acute Promyelocytic Leukemia (APL) in Canada: A Report From Cyp-C PEDIATRIC BLOOD & CANCER, 2025.

Prognostic Impact of Age at Diagnosis in Pediatric Acute Myeloid Leukemia (AML) in Canada: A Report From CYP-C PEDIATRIC BLOOD & CANCER, 2025.

Pharmacogenomic Analyses of Asparaginase-Related Toxicities in Acute Lymphoblastic Leukemia: A Report From the DFCI ALL Consortium Protocol 16-001 PEDIATRIC BLOOD & CANCER, 2025.

Molecular signatures associated with venous thromboembolism in children with acute lymphoblastic leukemia JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2025. DOI 10.1016/J.JTHA.2024.12.007

Incidence of Venous Thromboembolism in Pediatric Sarcoma Patients: A Systematic Review PEDIATRIC BLOOD & CANCER, 2025.

Impact of obesity on outcome in children diagnosed with cancer in Canada: A report from Cancer in Young People in Canada CANCER, 2025. DOI 10.1002/CNCR.35673

Efficacy and safety of thrombolysis for pediatric venous thromboembolism: a systematic review and meta-analysis BLOOD ADVANCES, 2025. DOI 10.1182/BLOODADVANCES.2025017058

Do Serum Asparaginase Activity Levels Predict Toxicity in Children and Adolescents With Acute Lymphoblastic Leukemia? PEDIATRIC BLOOD & CANCER, 2025.

Catheter-related risk factors for neonatal venous thrombo-embolism: A systematic review of the literature BLOOD, 2025. DOI 10.1182/BLOOD-2025-1353

Cancer Incidence and Outcome Among Infants in Canada: A Report From Cyp-C PEDIATRIC BLOOD & CANCER, 2025.

American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients BLOOD ADVANCES, 2025. DOI 10.1182/BLOODADVANCES.2024015328

Incidence of adverse events related to intravenous immunoglobulin therapy in children Transfusion, 2025/01. Jade Côté, Mathilde Chaloult‐Lavoie, Élisabeth Poulin, Laurence A. Hayes, Mahukpe Narcisse U. Singbo, Pierre Ouellet, Marie‐Claude Pelland‐Marcotte. DOI 10.1111/trf.18083

Clinical characteristics and outcomes of SARS-CoV-2 infection in pediatric oncology patients in the province of Quebec 2024/01/31. André Ilinca, Nawar Dakhallah, Amalia Souza, Jessica Liu, Samuel Bérubé, Josee Brossard, Catherine Vezina, Marie-Claude Pelland-Marcotte, Raoul Santiago, Thai Hoa Tran. DOI 10.22541/au.170669435.59625011/v1

VERY EARLY DIAGNOSIS AND MANAGEMENT OF CONGENITAL ERYTHROPOIETIC PORPHYRIA AT BIRTH 2024/01/30. Marie-Pier Desjardins, Lamia Naccache, Audrey Hébert, Isabelle Auger, Pierre Teira, Marie-Claude Pelland-Marcotte. DOI 10.22541/au.170665855.54975829/v1

Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis BLOOD, 2024. DOI 10.1182/BLOOD-2024-212166

The impact of comparative genomic hybridization/single-nucleotide polymorphism microarray in risk stratification of pediatric acute lymphoblastic leukemia PEDIATRIC BLOOD & CANCER, 2024. DOI 10.1002/PBC.31129

Second malignant neoplasms within 5 years from first primary diagnosis in pediatric oncology patients in Canada: a population-based retrospective cohort study (vol 14, 1376652, 2024) FRONTIERS IN ONCOLOGY, 2024. DOI 10.3389/FONC.2024.1418512

Second malignant neoplasms within 5 years from first primary diagnosis in pediatric oncology patients in Canada: a population-based retrospective cohort study FRONTIERS IN ONCOLOGY, 2024. DOI 10.3389/FONC.2024.1376652

Risk factors and clinical impact of thrombosis during induction chemotherapy for pediatric acute lymphoblastic leukemia: A report from CYP-C AMERICAN JOURNAL OF HEMATOLOGY, 2024. DOI 10.1002/AJH.27171

Real-world data of the use of rivaroxaban in pediatric patients with hematologic malignancies LEUKEMIA & LYMPHOMA, 2024. DOI 10.1080/10428194.2023.2300719

Prevalence of obesity and its impact on outcome in children diagnosed with cancer in Canada: A population-based study JOURNAL OF CLINICAL ONCOLOGY, 2024.

Impact of Obesity on Anticoagulation Dosing and Clinical Outcomes in Pediatric Patients with Venous Thrombo-Embolism BLOOD, 2024. DOI 10.1182/BLOOD-2024-194254

Clinical Significance of Incidental Central Venous Catheter-Related Thrombosis in Children Previously Treated for Cancer BLOOD, 2024. DOI 10.1182/BLOOD-2024-194341

Clinical Outcomes of Neonatal Central Line-Related Thrombosis: A Multicentric Retrospective Cohort Study BLOOD, 2024. DOI 10.1182/BLOOD-2024-205424

Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis BLOOD, 2024. DOI 10.1182/BLOOD-2024-212150

A novel <i>FGG</i> missense variant associated with fibrinogen storage disease in a large family from Quebec HAEMOPHILIA, 2024. DOI 10.1111/HAE.15006

Very Early Diagnosis and Management of Congenital Erythropoietic Porphyria CLINICAL PEDIATRICS, 2023. DOI 10.1177/00099228221128661

Update: Clinical characteristics and outcomes of SARS-CoV-2 infection in pediatric oncology patients in the province of Quebec PEDIATRIC BLOOD & CANCER, 2023. DOI 10.1002/PBC.29936

Trends of Obesity over Time and Its Prognostic Significance in Children and Adolescents with Newly-Diagnosed Acute Lymphoblastic Leukemia in Canada: A Population-Based Study BLOOD, 2023. DOI 10.1182/BLOOD-2023-178401

Rivaroxaban for Management of Venous Thromboembolism in Pediatric Nephrotic Syndrome; a Case Report and Review of Literature PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2023. DOI 10.1080/08880018.2022.2150797

REAL-WORLD DATA OF THE USE OF RIVAROXABAN IN PEDIATRIC PATIENTS WITH HEMATOLOGIC MALIGNANCIES PEDIATRIC BLOOD & CANCER, 2023.

French Canadian cross-cultural adaptation of CAPTSure©, an index for the Clinical Assessment of Post-Thrombotic Syndrome in children JOURNAL OF PATIENT-REPORTED OUTCOMES, 2023. DOI 10.1186/S41687-023-00622-7

COVID-19-associated coagulopathy in children: A multicenter observational cohort study PEDIATRIC BLOOD & CANCER, 2023. DOI 10.1002/PBC.30079

Biomarkers in pediatric venous thromboembolism: a systematic review of the literature JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2023. DOI 10.1016/J.JTHA.2023.03.012

Between Scylla and Charybdis: thrombosis in children with hemophilia FRONTIERS IN PEDIATRICS, 2023. DOI 10.3389/FPED.2023.1173549

Rivaroxaban for management of venous thromboembolism in pediatric nephrotic syndrome; a case report and review of literature 2022/04/09. Marie-Claude Pelland-Marcotte, Soumitra Tole, Eve Bouhelier, Susan Lee, Jessica Halparin, Cherry Mammen, Karen Lyons, Ali Amid. DOI 10.22541/au.164949123.38497885/v1

Thrombosis and Thromboprophylaxis in Pediatric Patients Admitted with COVID-19 Infection -- A Prospective Multicenter Observational Cohort Study 2022/03/10. Alexandra Zabeida, Rochelle Winikoff, Marie-Claude Pelland-Marcotte, Janie Charlebois, Christine Sabapathy. DOI 10.22541/au.164688916.60103016/v1

Ribosomal translational regulation is a potential mechanism for leukemia-related thromboembolic event in childhood acute lymphoblastic leukemia CANCER RESEARCH, 2022.

Prognostic factors and outcomes of infant acute lymphoblastic leukemia (ALL), hypodiploid ALL, and mixed-phenotype acute leukemia (MPAL) in Canada: a report from CYP-C LEUKEMIA & LYMPHOMA, 2022. DOI 10.1080/10428194.2022.2118536

Post-procedural bleeding rate and haemostatic treatment use for dental procedures before and after the implementation of a standardized protocol for people with inherited bleeding disorders HAEMOPHILIA, 2022. DOI 10.1111/HAE.14609

Clinical characteristics and outcomes of SARS-CoV-2 infection in pediatric oncology patients in the province of Quebec PEDIATRIC BLOOD & CANCER, 2022. DOI 10.1002/PBC.29572

Children with Acute Lymphoblastic Leukemia and Early Thrombosis Have Dysregulated Coagulation-Related Genes and Pathways BLOOD, 2022. DOI 10.1182/BLOOD-2022-163334

Central Line Related Thrombosis in Neonates: A Population- based Study PEDIATRICS, 2022.

Acute Management of High-Risk and Intermediate-Risk Pulmonary Embolism in Children A Review CHEST, 2022. DOI 10.1016/J.CHEST.2021.09.019

Thrombosis is associated with worse survival in children with acute lymphoblastic leukemia: A report from CYP-C AMERICAN JOURNAL OF HEMATOLOGY, 2021. DOI 10.1002/AJH.26193

The First Wave of The Covid-19 Pandemic Did Not Affect Childhood Cancer Incidence In Canada: A Report from Cyp-C PEDIATRIC BLOOD & CANCER, 2021.

Prognostic Factors and Outcomes of Infant Acute Lymphoblastic Leukemia (All), Hypodiploid All and Mixed-Phenotype Acute Leukemia (MPAL) In Canada: A Population-Based Study PEDIATRIC BLOOD & CANCER, 2021.

OUTCOMES PREDICTORS OF INFANT ALL, HYPODIPLOID ALL AND MPAL IN CANADA: A POPULATION-BASED STUDY PEDIATRIC BLOOD & CANCER, 2021.

Infections as a potential long-term risk following childhood leukemia (vol 137, 109554, 2020) MEDICAL HYPOTHESES, 2021.

Incidence of childhood cancer in Canada during the COVID-19 pandemic CANADIAN MEDICAL ASSOCIATION JOURNAL, 2021. DOI 10.1503/CMAJ.210659

Distance to the pediatric oncology center does not affect survival in children with acute lymphoblastic leukemia: a report from CYP-C LEUKEMIA & LYMPHOMA, 2021. DOI 10.1080/10428194.2020.1849673

Case - Bilateral and recurrent pediatric cystic nephroma associated with DICER1 mutation CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2021. DOI 10.5489/CUAJ.6836